Can Alzheimer’s treatment now be taken at home?

A weekly subcutaneous form of lecanemab can reduce infusion-center visits for eligible people with early Alzheimer’s, but monitoring still matters.

In China, regulators approved LEQEMBI’s subcutaneous initiation treatment for early Alzheimer’s in September; the US approved the 500 mg weekly initiation option in July. The autoinjector uses two 250 mg shots at home instead of a biweekly IV visit. Lecanemab is an anti-amyloid antibody that can slow decline for some people with mild cognitive impairment or mild dementia due to Alzheimer’s—it does not cure the disease or restore lost memory.

Diagnosis, eligibility, MRI monitoring, and known safety risks still require a specialist.

Why treatment at home does not mean treatment alone

Moving an injection home removes travel and infusion-center time. It does not remove the medicine's risks or the checks around it. Lecanemab can cause serious side effects, including brain swelling or bleeding in some people, so diagnosis, eligibility checks, and MRI monitoring remain part of treatment.

What to do, step by step

1. Understand what the medicine can and cannot do: it can slow decline for some people; it is not a cure.
2. Eligibility starts with a confirmed diagnosis of early Alzheimer's from a specialist.
3. Expect ongoing monitoring, including MRI scans, even when injections happen at home.
4. Learn the autoinjector from the care team before the first home dose.
5. Keep a simple record of doses and anything new you notice for the care team.